Drugs for cancer and alcoholism show promise for RP
With all the interest in exciting gene and cell therapies for inherited sight loss, it’s easy to forget that more traditional drugs can also hold promise.
Search
Search results
Joint statement on benefits and employment support
As a coalition of sight loss charities, we are calling on the Government to make the benefit system and employment support fit for purpose for blind and partially sighted people.
Flipping the switch on RP: SparingVision doses patients in their first in-human clinical trial for SPVN20
The latest research news from Retina UK.
Belite Bio announces promising phase 3 results for Stargardt disease
The latest research news from Retina UK.
PDE6A gene therapy trial report: the importance of scientific learnings in an unsuccessful trial
Researchers from the University Hospital Tübingen in Germany recently announced that there were no signs of visual gains in an early-phase clinical trial of a PDE6A gene therapy for Retinitis Pigmentosa (RP).
Edinburgh Local Peer Support Group
Saturday 11 April 2026, 11.00am - 1.00pm - In-person - Come and join Valerie and the group for our first meeting of 2026 when we return to the Festival Theatre, Edinburgh to hear from guest speaker Chloe Brotherton, PhD Student working with Dr Roly Megaw.
South Wales Local Peer Support Group
Tuesday 12 May 2026, 7.00pm - 8.00pm - via Zoom - Please come and join facilitator Stuart Francis and our new South Wales Peer Support Group where we are delighted to welcome guest speaker Becs Harris, Wellbeing Service Manager at Sight Cymru.
For professionals
Information for healthcare professionals: Genetic testing and counselling in inherited retinal disease
Brain stimulation may reduce hallucinations
UK researchers have discovered that passing a weak electrical current between electrodes on a person’s scalp may lead to a reduction in frequency of the visual hallucinations experienced by some people living with sight loss.
Opus genetics launches clinical trial for MERTK-related retinitis pigmentosa
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.